Impact Factor 4.416

Frontiers journals are at the top of citation and impact metrics

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Oncol. | doi: 10.3389/fonc.2018.00388

VHL-mediated regulation of CHCHD4 and mitochondrial function.

 Thomas Briston1, Jenna Stephens2,  Luke W. Thomas2, Cinzia Esposito2,  Yuen-Li Chung3, Saiful Syafruddin2,  Mark Turmaine1, Lucas Maddalena2, Basma Greef2,  Gyorgy Szabadkai1, Patrick Maxwell2, Sakari Vanharanta2 and  Margaret Ashcroft2*
  • 1University College London, United Kingdom
  • 2University of Cambridge, United Kingdom
  • 3Institute of Cancer Research (ICR), United Kingdom

Dysregulated mitochondrial function is associated with the pathology of a wide range of diseases including renal disease and cancer. Thus, investigating regulators of mitochondrial function is of particular interest. Previous work has shown that the von Hippel-Lindau tumor suppressor protein (pVHL) regulates mitochondrial biogenesis and respiratory chain function. pVHL is best known as an E3-ubiquitin ligase for the α-subunit of the hypoxia inducible factor (HIF) family of dimeric transcription factors. In normoxia, pVHL recognizes and binds hydroxylated HIF-α (HIF-1α and HIF-2α), targeting it for ubiquitination and proteasomal degradation. In this way, HIF transcriptional activity is tightly controlled at the level of HIF-α protein stability. At least 80% of clear cell renal carcinomas exhibit inactivation of the VHL gene, which leads to HIF-α protein stabilization and constitutive HIF activation. Constitutive HIF activation in renal carcinoma drives tumor progression and metastasis. Reconstitution of wild-type VHL protein (pVHL) in pVHL-defective renal carcinoma cells not only suppresses HIF activation and tumor growth, but also enhances mitochondrial respiratory chain function via mechanisms that are not fully elucidated.
Here, we show that pVHL regulates mitochondrial function when re-expressed in pVHL-defective 786O and RCC10 renal carcinoma cells distinct from its regulation of HIF-α. Expression of CHCHD4, a key component of the disulphide relay system (DRS) involved in mitochondrial protein import within the intermembrane space (IMS) was elevated by pVHL re-expression alongside enhanced expression of respiratory chain subunits of complex I (NDUFB10) and complex IV (mtCO-2 and COX IV). These changes correlated with increased oxygen consumption rate (OCR) and dynamic changes in glucose and glutamine metabolism. Knockdown of HIF-2α also led to increased OCR, and elevated expression of CHCHD4, NDUFB10 and COXIV in 786O cells. Expression of pVHL mutant proteins (R200W, N78S, D126N and S183L) that constitutively stabilize HIF-α but differentially promote glycolytic metabolism, were also found to differentially promote the pVHL-mediated mitochondrial phenotype. Parallel changes in mitochondrial morphology and the mitochondrial network were observed. Our study reveals a new role for pVHL in regulating CHCHD4 and mitochondrial function in renal carcinoma cells.

Keywords: von Hippel-Lindau protein (pVHL), Hypoxia Inducible Factor, Mitochondria, Bioenergetics, Metabolism, CHCHD4, respiratory chain.

Received: 06 Apr 2018; Accepted: 29 Aug 2018.

Edited by:

Massimo Bonora, Department of Cell Biology, Albert Einstein College of Medicine, United States

Reviewed by:

Valeria Poli, Università degli Studi di Torino, Italy
Keith R. Laderoute, SRI International, United States  

Copyright: © 2018 Briston, Stephens, Thomas, Esposito, Chung, Syafruddin, Turmaine, Maddalena, Greef, Szabadkai, Maxwell, Vanharanta and Ashcroft. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Prof. Margaret Ashcroft, University of Cambridge, Cambridge, United Kingdom, m.ashcroft@medschl.cam.ac.uk